SEC
TEVA icon

Seven Eight Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Seven Eight Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41,779
Closed -$753K – 582
2024
Q3 		$753K Sell
41,779
-43,375
-51% -$759K 0.07% 474
2024
Q2 		$1.38M Buy
+85,154
New +$1.31M 0.14% 245
2023
Q3 		– Sell
-12,260
Closed -$92.3K – 742
2023
Q2 		$92.3K Sell
12,260
-57,849
-83% -$469K 0.02% 470
2023
Q1 		$620K Sell
70,109
-1,188
-2% -$11.7K 0.13% 209
2022
Q4 		$650K Buy
+71,297
New +$622K 0.17% 181
2022
Q3 		– Sell
-168,607
Closed -$1.27M – 627
2022
Q2 		$1.27M Sell
168,607
-238,748
-59% -$2.08M 0.51% 42
2022
Q1 		$3.83M Buy
407,355
+238,158
+141% +$1.99M 0.51% 49
2021
Q4 		$1.35M Sell
169,197
-164,524
-49% -$1.48M 0.24% 130
2021
Q3 		$3.25M Buy
333,721
+197,295
+145% +$1.85M 0.31% 96
2021
Q2 		$1.35M Buy
+136,426
New +$1.44M 0.19% 184
2020
Q2 		– Sell
-21,200
Closed -$190K – 548
2020
Q1 		$190K Buy
+21,200
New +$217K 0.05% 402
2019
Q4 		– Sell
-35,845
Closed -$247K – 769
2019
Q3 		$247K Sell
35,845
-1,170,300
-97% -$8.97M 0.01% 558
2019
Q2 		$11.1M Buy
+1,206,145
New +$14.5M 0.59% 38
2019
Q1 		– Sell
-221,679
Closed -$3.42M – 726
2018
Q4 		$3.42M Buy
+221,679
New +$4.54M 0.19% 151
2017
Q2 		– Sell
-17,100
Closed -$549K – 673
2017
Q1 		$549K Buy
17,100
+15,500
+969% +$529K 0.11% 255
2016
Q4 		$58K Sell
1,600
-75,500
-98% -$3.01M 0.01% 497
2016
Q3 		$3.55M Buy
+77,100
New +$4.02M 1.04% 8
2016
Q2 		– Sell
-31,800
Closed -$1.7M – 667
2016
Q1 		$1.7M Buy
31,800
+28,200
+783% +$1.65M 0.72% 25
2015
Q4 		$236K Buy
+3,600
New +$222K 0.16% 207
2015
Q2 		– Sell
-800
Closed -$50K – 657
2015
Q1 		$50K Buy
+800
New +$46.5K 0.08% 284
2014
Q2 		– Sell
-7,500
Closed -$396K – 592
2014
Q1 		$396K Buy
+7,500
New +$347K 0.34% 102

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Seven Eight Capital's TEVA Position: Q4 2024 in Review

Seven Eight Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 41,779 shares — an estimated $753K sold.

Seven Eight Capital first reported a position in TEVA in Q1 2014 and held it in 21 quarters. The position peaked at $11.1M in Q2 2019. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Seven Eight Capital reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 41,779 Teva Pharmaceuticals shares in Q4 2024, an estimated $753K.
  • Seven Eight Capital first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 21 quarters.
  • Seven Eight Capital's Teva Pharmaceuticals position peaked at $11.1M in Q2 2019.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.